Related Experiment Videos
Repeated PCR in CML during IFN-alpha therapy
A M Liberati1, E Donti, C Rosso
1Institute of Internal Medicine and Oncology Science, University of Perugia, Italy.
European Journal of Haematology
|March 1, 1994
Summary
Two of four chronic myeloid leukemia (CML) patients achieved PCR negativity during interferon-alpha (IFN-alpha) therapy. Relapse occurred in two patients, one while on therapy, indicating variable responses to IFN-alpha treatment.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome (Ph).
- Interferon-alpha (IFN-alpha) has been a cornerstone therapy for CML, aiming for molecular remission.
Purpose of the Study:
- To assess the molecular response, specifically using PCR, in CML patients treated with IFN-alpha.
- To monitor for cytogenetic relapse in patients achieving or maintaining remission.
Main Methods:
- Bone marrow and peripheral blood samples from four CML patients in complete cytogenetic remission were analyzed using repeated PCR.
- Patients were undergoing treatment with IFN-alpha, with dose adjustments and monitoring over time.
Main Results:
- Two patients achieved polymerase chain reaction (PCR) negativity, indicating molecular remission.
- One patient initially became PCR-negative but reverted to PCR positivity after IFN-alpha dose reduction, yet remained Philadelphia chromosome-negative (Ph'-negative).
- Two patients remained persistently PCR-positive, and both experienced cytogenetic relapse, one during ongoing therapy.
Conclusions:
- IFN-alpha treatment elicits variable molecular responses in CML patients.
- Persistent PCR positivity may herald cytogenetic relapse, even during therapy.
- Monitoring PCR status is crucial for managing CML patients on IFN-alpha therapy and detecting relapse.